Dr. Mark Behlke has directed R&D at IDT since 1995. He is also a scientific co-founder of Dicerna Pharmaceuticals in Boston. Before joining IDT, he was a physician postdoctoral fellow of the Howard Hughes Medical Institute at the Whitehead Institute, MIT, and a resident physician in internal medicine at Brigham and Women’s Hospital. Mark received his M.D/Ph.D. degrees from Washington University in 1988 and his B.S. degree from MIT in 1981. Mark is an inventor on over 50 issued U.S. patents and is an author on over 135 scientific publications and book chapters. He is a recognized expert on oligonucleotide-based technologies.